Obesity Drugs Among Those Being Examined for Efficacy Against NASH

Obesity Drugs Among Those Being Examined for Efficacy Against NASH

Newly popular obesity drugs like Ozempic® and Wegovy® are among several undergoing clinical trials at Mount Sinai for nonalcoholic steatohepatitis, or NASH. If the trials are successful, they would fill an important gap, as no medications are currently approved by the FDA for the growing population with this disease.

4 minute read

No drugs are currently approved by the Food and Drug Administration (FDA) for the treatment of nonalcoholic steatohepatitis (NASH). But that may be about to change, thanks to work by Mount Sinai researchers who are conducting trials on a number of medications with different mechanisms of action against the growing threat.

Among the medications in trials for NASH are new drugs for treating diabetes and obesity that have been recently in the spotlight, says Meena Bansal, MD, Director of the NASH Center of Excellence and Professor of Medicine (Liver Diseases) at the Icahn School of Medicine at Mount Sinai.

“Both of those comorbidities are present in many people with NASH, and we know that if you lose 10 percent of your body weight, you can see improvement in NASH-related fibrosis,” Dr. Bansal says.

We know that if you lose 10 percent of your body weight, you can see improvement in NASH-related fibrosis.

- Meena Bansal, MD

Among the trials she and her team are running is a phase 3 trial involving semaglutide (sold under brand names that include Ozempic® and Wegovy®). A previous study published in 2021 in The New England Journal of Medicine found that patients treated with semaglutide experienced significantly more NASH resolution than those on placebo. But the secondary endpoint—improvement in fibrosis stage with no worsening of NASH—produced inconclusive results because of unusually high rates of response in the placebo group and overall small numbers.

The Mount Sinai trial, begun in 2022 and sponsored by the drug’s maker, Novo Nordisk, seeks to examine whether a weekly subcutaneous dose of 2.4 mg of semaglutide—the standard dose used for treating obesity—can improve either NASH or the degree of fibrosis, versus placebo, in patients with NASH and fibrosis stages 2 and 3 (F2 and F3).

The trial’s primary endpoint will be either NASH resolution without worsening of fibrosis, or at least a one-stage regression of fibrosis without worsening NASH. Patients will be assessed via biopsy at 72 weeks and will continue to be followed for a total of 240 weeks and assessed for clinical outcomes ranging from esophageal bleeding to liver transplant.

The trial is one of eight at the NASH Center of Excellence that are currently seeking to enroll patients. Three of those trials involve resmetirom, a thyroid hormone receptor-β agonist; other drugs under investigation include lisinopril, an angiotensin-converting enzyme inhibitor, and lanifibranor, a pan-peroxisome proliferator–activated receptor agonist.

The resmetirom trials, for which Dr. Bansal is also the Principal Investigator, are exploring the hypothesis that non-alcoholic fatty liver disease (NAFLD) is a result of relative intrahepatic hypothyroidism, and that increasing thyroid hormone signaling in the liver can lead to NASH resolution with no worsening of fibrosis, or at least a one-stage improvement in fibrosis with no worsening of NASH.

The initial phase 2 trial found that daily oral resmetirom resulted in a significant reduction in liver fat content at 12 and 36 weeks compared with placebo. Resmetirom responders with >30 percent magnetic resonance imaging proton density fat fraction (MRI-PDFF) reduction at week 12 had higher rates of NASH resolution (37 percent) on week 36 liver biopsy compared with nonresponders (4 percent), suggesting that early MRI-PDFF response could predict future histologic improvement. Resmetirom also positively affected patients’ lipid profiles by reducing blood levels of atherogenic lipids. Thus, it may reduce the incidence of cardiovascular disease, which is the leading cause of mortality in patients with NASH.

Recent topline data from the phase 3 trial looking at liver biopsies after 52 weeks of treatment suggests that resmetirom can cause both improvement of at least one stage in fibrosis and NASH resolution in a subset of patients. The sponsor, Madrigal Pharmaceuticals, will be submitting these data to the FDA for accelerated approval.

The ongoing studies at Mount Sinai are looking to see if continued therapy will ultimately improve liver-related outcomes.

A third drug, obeticholic acid (OCA), was furthest along in trials; however, an FDA advisory panel voted in May 2023 against accelerated approval of it to treat NASH and the FDA followed with a rejection of accelerated approval in June 2023, citing safety concerns. The decision came despite a trial, known as REGENERATE and led by Dr. Bansal as PI, that met its primary endpoint of an improvement in fibrosis by one stage without worsening of NASH. Based on this disappointing news, the drug's maker, Intercept Pharmaceuticals Inc., has decided to halt further development of this compound for NASH.

The wave of medications progressing through clinical trials marks a sea change for the treatment of NASH, Dr. Bansal says.

“It has been very challenging to get NASH therapeutics to market,” she says. “Early optimism was dashed by the failure of numerous trials. However, the promising data for these newer medications should make us optimistic that we will finally have effective treatments for this growing condition.”


Meena Bansal, MD

Meena Bansal, MD

Professor of Medicine (Liver Diseases) at Icahn Mount Sinai; Director of the NASH Center of Excellence